A real world study of apatinib combined with gefitinib in the treatment of EGFR-positive advanced non-squamous non-small cell lung cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039246

Enrollment

Unknown

Registered

2020-10-22

Start date

2020-10-10

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EGFR-positive advanced non-squamous non-small cell lung cancer

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, no gender limit; 2. EGFR-positive advanced non-squamous non-small cell lung cancer patients, including: First-line treatment for patients with relapse or metastasis (allowing patients who relapse within 6 months after completion of adjuvant treatment to be included in the group); Note: Adjuvant therapy allows the use of chemotherapy or EGFR-TKIs. Patients who can continue to use EGFR-TKIs after the first-line EGFR-TKIs treatment progresses; 3. Volunteer to join the study and sign the informed consent form; 4. Researchers think it can benefit.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with contraindications to apatinib or EGFR-TKIs (eg: active bleeding, ulcers, intestinal perforation, intestinal obstruction, drug-uncontrollable hypertension, grade III-IV cardiac insufficiency, within 30 days after major surgery , Severe liver and kidney dysfunction, etc.); 3The doctor thinks it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
PFS;DOR;	—

Secondary

Measure	Time frame
OS;ORR;DCR;	—

Countries

China

Contacts

Public ContactKangsheng Gu

The First Affiliated Hospital of Anhui Medical University

869162101@qq.com+86 13805692145

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026